Complement, Cardiovascular Disease, and SLE

补体、心血管疾病和系统性红斑狼疮

基本信息

  • 批准号:
    6898927
  • 负责人:
  • 金额:
    $ 34.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2007-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Inflammation is now recognized as a critical process in the development and rupture of atherosclerotic plaques, and in the morbidity and mortality that result from cardiovascular disease. Recent studies have also suggested that this process may be accelerated and exaggerated in patients with systemic lupus erythematosus. We have recently established a research program focused on vascular biology and pathology, with a focus on lupus as a model of accelerated atherosclerosis. The stimulus for these investigations was a recent surprising observation by Manzi and colleagues who demonstrated a strong linear association between elevated serum levels of C3 and C4 and aortic stiffness in premenopausal women with SLE. Whereas decreased serum levels of C3 and C4 have traditionally been used to monitor disease activity in patients with SLE, association of elevated serum levels of serum complement components with any disease process is unprecedented. This observation led us to investigate the potential role(s) for complement C3 and C4 in the immunopathogenesis of cardiovascular disease in SLE. Vascular imaging studies led to several intriguing and unexpected observations that will be further explored here. First, we discovered that complement components C3 and C4 are present in several distinct patterns within the arterial walls of both humans and mice. Specifically, proteolytic fragments of C3 and C4 co-localize with, and may be covalently bound to, elastin within the arterial wall. This entirely unexpected observation suggested that complement deposition within the arterial wall may increase vascular stiffness, an early event in atherosclerosis, through direct interference with elastic fiber flexibility. Second, we observed aggregates of complement deposition within the vessel wall, the site at which plaque formation is now known to initiate. Third, we demonstrated that complement components are specifically present within the vasculature of mice with lupus-like syndromes as compared with controls. These observations, together with those of Manzi and colleagues, have led to the following specific aims that are based on our central hypothesis that the complement system may influence vascular stiffness and contribute significantly to the atherosclerotic process by directly reducing vascular elasticity within the arterial wall. The long-term goal of this proposal is to perform an initial characterization of the role of the complement system in atherosclerosis, using normal and abnormal human and mouse vascular systems. Specific Aim 1 is to characterize the spatial and temporal localization of complement proteins C3 and C4 within the arterial wall. Specific Aim 2 is to characterize the distribution of complement C3 and C4 within the arterial tree. Specific Aim 3 is to determine the capacity of complement C3 and C4 within the arterial wall to increase arterial stiffness. These studies will represent the first rigorous investigation of the role of the complement system in atherosclerosis, using SLE as a model of accelerated coronary vascular disease. Ultimately, the data generated by the proposed studies should identify therapeutic targets in SLE and in atherosclerosis in general.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph M Ahearn其他文献

Joseph M Ahearn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph M Ahearn', 18)}}的其他基金

Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    6805641
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6772602
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    7105057
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6924619
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    6733758
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Complement, Cardiovascular Disease, and SLE
补体、心血管疾病和系统性红斑狼疮
  • 批准号:
    7077805
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in Systemic Lupus Erythematosus
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    7253944
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
Erythrocytes as Time Capsules of Disease Activity in SLE
红细胞作为系统性红斑狼疮疾病活动的时间胶囊
  • 批准号:
    6677400
  • 财政年份:
    2003
  • 资助金额:
    $ 34.81万
  • 项目类别:
DAMAGE AND PATHOLOGIC FRACTURE IN VERTEBRAL BODIES
椎体损伤和病理性骨折
  • 批准号:
    6232932
  • 财政年份:
    2001
  • 资助金额:
    $ 34.81万
  • 项目类别:
Rheumatic Diseases Core Center
风湿病核心中心
  • 批准号:
    6632786
  • 财政年份:
    2001
  • 资助金额:
    $ 34.81万
  • 项目类别:

相似海外基金

Clinical Research and Regulatory Support Core
临床研究和监管支持核心
  • 批准号:
    10474450
  • 财政年份:
    2021
  • 资助金额:
    $ 34.81万
  • 项目类别:
ACR Basic and Clinical Research Conference: Rheumatologic Complications of Emerging Viral Infections / SARS-CoV-2
ACR 基础与临床研究会议:新发病毒感染的风湿病并发症 / SARS-CoV-2
  • 批准号:
    10318355
  • 财政年份:
    2021
  • 资助金额:
    $ 34.81万
  • 项目类别:
Clinical Research and Regulatory Support Core
临床研究和监管支持核心
  • 批准号:
    10685401
  • 财政年份:
    2021
  • 资助金额:
    $ 34.81万
  • 项目类别:
Clinical Research and Regulatory Support Core
临床研究和监管支持核心
  • 批准号:
    10281549
  • 财政年份:
    2021
  • 资助金额:
    $ 34.81万
  • 项目类别:
Rare Diseases Clinical Research Scholar’s Program
罕见疾病临床研究学者计划
  • 批准号:
    10198146
  • 财政年份:
    2020
  • 资助金额:
    $ 34.81万
  • 项目类别:
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research
西北核心临床研究站点:艾滋病毒/艾滋病研究的跨组学
  • 批准号:
    10223024
  • 财政年份:
    2019
  • 资助金额:
    $ 34.81万
  • 项目类别:
UNC MACS/WIHS Combined Cohort Study Clinical Research Site
北卡罗来纳大学 MACS/WIHS 联合队列研究临床研究网站
  • 批准号:
    10213367
  • 财政年份:
    2019
  • 资助金额:
    $ 34.81万
  • 项目类别:
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research
西北核心临床研究站点:艾滋病毒/艾滋病研究的跨组学
  • 批准号:
    10214768
  • 财政年份:
    2019
  • 资助金额:
    $ 34.81万
  • 项目类别:
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research
西北核心临床研究站点:艾滋病毒/艾滋病研究的跨组学
  • 批准号:
    9927860
  • 财政年份:
    2019
  • 资助金额:
    $ 34.81万
  • 项目类别:
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS Research
西北核心临床研究站点:艾滋病毒/艾滋病研究的跨组学
  • 批准号:
    9912209
  • 财政年份:
    2019
  • 资助金额:
    $ 34.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了